AZ1495

SKU: orb1308616

Description

AZ1495 is a potent and orally bioavailable small molecule inhibitor of IRAK4 (IC50=5 nM) and IRAK1 (IC50=23 nM). It demonstrates research utility in models of diffuse large B-cell lymphoma, particularly for investigating oncogenic signaling driven by the MYD88L265P mutation in both cellular and in vivo studies.

Research Area

Cell Biology, Immunology & Inflammation, Signal Transduction

Key Properties

• CAS Number: 2196204-23-4
• MW: 385.5
• Purity: 98.81% (May vary between batches)
• Formula: C₂₁H₃₁N₅O₂
• SMILES: C1CC(CCO1)c1c[nH]c2ncnc(N[C@H]3CC[C@@H](CC3)N3CCOCC3)c12
• Target: IRAK,CDK,Haspin Kinase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.59 mM);DMSO:10 mg/mL (25.94 mM)

Bioactivity

• Target IC50:
  IRAK4:5 nM|CLK2:5 nM|CLK4:8 nM|CLK1:50 nM|Haspin:4 nM|IRAK1:23 nM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cancer, AZ1495, AZ-1495, AZ 1495, CLK4, CLK2, CLK1, diffuse large B-cell lymphoma (DLBCL), Inhibitor, haspin, Haspin Kinase, HaspinKinase, inhibit, IRAK4, IRAK, IRAK-1, IRAK1, IL-1R associated kinase, interleukin-1 receptor associated kinase 1 (IRAK1), interleukin-1 receptor associated kinase 4 (IRAK4), Interleukin-1 receptor associated kinase, weak base

Compound Identifiers

PubChem CID

131839619